New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News For ABT;FB;ALDW;ALJ;LRCX;WES;ABBV;WGP;WHF From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | 5 | all recent news | >>
October 14, 2014
19:46 EDTABBVAbbVie board reconsidering recommendation to holders to accept Shire merger
Subscribe for More Information
12:41 EDTABBVGilead retreats following Johnson & Johnson comments on HCV drug
Shares of Gilead (GILD), which has developed a hepatitis C treatment, are retreating after Johnson & Johnson (JNJ) said it would seek to make its own hepatitis C treatment accessible and competitive. Some investors believe that Johnson & Johnson's comments suggest that it will cut the price of its hepatitis C drug. WHAT'S NEW: Johnson & Johnson said on its earnings conference call today that it was "committed" to its treatment for hepatitis C virus, or HCV. The company added that it intends to remain competitive in the space and would look to make its HCV treatment, Olysio, accessible. In a separate development today, The Wall Street Journal reported that Abbvie (ABBV), which also has an HCV treatment, may have to consider pricing its HCV drug more aggressively after Gilead received FDA approval for Harvoni, the first combination pill approved to treat chronic HCV genotype 1 infection. One analyst quoted by The Journal, Roger Longman, said that AbbVie should consider pricing its drug at $76,000 for a 12 week regimen, representing a 20% discount to Harvoni, which will be priced at $94,500 for a full 12 week regimen. ANALYST REACTION: In a note to investors earlier today, RBC Capital analyst Michael Yee wrote that the weakness in Gilead's stock today has created a buying opportunity. Johnson & Johnson probably can't reduce the price of its Olysio drug much, since it is often used in combination with Gilead's Sovaldi, which costs $84,000 for 12 weeks, RBC Capital analyst Michael Yee wrote in a note to investors today. The price of AbbVie's treatment is unlikely to be much below Sovaldi's price, the analyst stated. WHAT'S NOTABLE: Gilead, along with a number of other drug companies, may also be under pressure because Ireland is reportedly closing its "Irish Double" tax loophole. Gilead is one of the companies that currently benefits from the "Irish Double," but Yee says that closing the loophole should only have a "minimal" impact on Gilead. PRICE ACTION: In early afternoon trading, Gilead fell 3.3% to $98.10, AbbVie gained 1.7% to $54.53 and Johnson & Johnson lost 0.6% to $98.52.
10:51 EDTABBVGilead weakness a buying opportunity, says RBC Capital
Subscribe for More Information
10:05 EDTABBVAbbVie could cause Hep C price tipping point with aggressive pricing, WSJ says
Subscribe for More Information
October 13, 2014
13:10 EDTFBGoogle's Schmidt says Amazon is company's biggest search rival, FT reports
Eric Schmidt, the executive chairman of Google (GOOG), says Amazon (AMZN) is his company's biggest rival in search, not Bing (MSFT) or Yahoo (YHOO), the Financial Times reports. Schmidt also argued in Berlin that Google should not be regulated "as if it were the gatekeeper of the internet," given the influence of Amazon and Facebook (FB). Reference Link
10:08 EDTALJ, LRCXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:39 EDTFBActive equity options trading on open
Subscribe for More Information
09:23 EDTABBVAbbVie's Humira for hidradenitis suppurativa meets Phase 3 trial endpoint
AbbVie announced new results from PIONEER II, a pivotal Phase 3 study, demonstrating the effect of Humira in reducing common clinical signs and symptoms in moderate-to-severe hidradenitis suppurativa, specifically the number of abscesses and inflammatory nodules. The results of this study, in combination with previously presented results from PIONEER I, will contribute to worldwide regulatory filings for an expanded use of Humira, which is not currently approved by regulatory authorities for the treatment of HS.
08:22 EDTLRCXLam Research upgraded to Conviction Buy from Buy at Goldman
Subscribe for More Information
07:39 EDTABBVPharmaceutical Care Management Association to hold annual meeting
Subscribe for More Information
07:37 EDTABBVAmerican Society of Anesthesiologists to hold annual meeting
Subscribe for More Information
05:49 EDTALJAlon USA Energy upgraded to Overweight from Underweight at Barclays
Subscribe for More Information
05:15 EDTFBFacebook, Ericsson, XL Axiata innovate to improve Indonesia network performance
Subscribe for More Information
October 10, 2014
16:02 EDTFBActionable Options for Friday, October, 10
Subscribe for More Information
11:13 EDTLRCXMicrochip not relevant to DRAM, NAND, says Summit Research
Subscribe for More Information
10:07 EDTFBFacebook, peer-to-peer lending groups in discussions, The Information says
Subscribe for More Information
07:57 EDTFBFacebook, India Telecom Minister discuss expanding in India, Economic Times says
Facebook CEO Mark Zuckerberg and India's Telecom Minister Ravi Shankar Prasad met to discuss expanding the reach of internet by using alternate technology, reports The Economic Times. According to sources, Facebook requested Prasad establish single point contact in his ministry for the alternative technology to which the minister immediately agreed. Reference Link
October 9, 2014
16:00 EDTFBOptions Update; October 9, 2014
Subscribe for More Information
08:28 EDTABBVGilead to be challenged by AbbVie in HCV near-term, says Bernstein
Subscribe for More Information
06:59 EDTFBFacebook has no imminent WhatsApp monetization goals, Reuters says
Subscribe for More Information
1 | 2 | 3 | 4 | 5 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use